Twitxy Saved

LIFE AI

This account is verified because it's an official organization on X. Learn more

@LifeNetwork_AI

The clinical-development coordination layer for AI-generated drugs | Discord: discord.gg/s3ekrgjuMR | Telegram: t.me/lifenetwork_ann
testnet.lifeai.io Joined March 2024
348 Following 50K Followers 1K Posts

Latest posts 5

Pinned post

LIFE AI @LifeNetwork_AI
๐—ก๐—ฉ๐—œ๐——๐—œ๐—” ๐—š๐—ง๐—– ๐—ง๐—ฎ๐—ถ๐˜„๐—ฎ๐—ป ๐Ÿฎ๐Ÿฌ๐Ÿฎ๐Ÿฒ - ๐— ๐—ฎ๐—ฝ๐—ฝ๐—ถ๐—ป๐—ด ๐˜๐—ต๐—ฒ #๐—›๐—ฒ๐—ฎ๐—น๐˜๐—ต๐—ฐ๐—ฎ๐—ฟ๐—ฒ๐—”๐—œ ๐—ฉ๐—ฎ๐—น๐˜‚๐—ฒ ๐—–๐—ต๐—ฎ๐—ถ๐—ป

At NVIDIA GTC Taiwan 2026, our Co-Founder & CEO Dr. Tuan Cao @tuan_lifeai presented โ€œLifeAI Biohub: A Purpose-built AI platform for Drug Developmentโ€

One signal emerged throughout the session:
As AI capabilities continue to advance, the bottleneck is no longer intelligence itself. It is the infrastructure that enables validation, governance, and coordination across the full spectrum of healthcare stakeholders.

๐—ง๐—ต๐—ฒ ๐—›๐—ฒ๐—ฎ๐—น๐˜๐—ต๐—ฐ๐—ฎ๐—ฟ๐—ฒ ๐—”๐—œ ๐—ฉ๐—ฎ๐—น๐˜‚๐—ฒ ๐—–๐—ต๐—ฎ๐—ถ๐—ป
Pharma โ†’ Hospitals โ†’ Doctors โ†’ Labs โ†’ Regulators โ†’ Auditors โ†’ Patients
Sustainable progress in healthcare AI demands alignment across the entire ecosystem, not isolated optimization within a single organization.

๐—Ÿ๐—ถ๐—ณ๐—ฒ๐—”๐—œ ๐—•๐—ถ๐—ผ๐—›๐˜‚๐—ฏ
Shared Infrastructure โ†’ Coordination Layer โ†’ Connected Network โ†’ Application Success

This is the foundation Life AI is building: the shared infrastructure and coordination layer for the healthcare AI value chain so that every application built on top can move faster, scale further, and earn trust across the industry.

The long-term opportunity in healthcare AI will not be defined by better models alone. It will be defined by the infrastructure that makes those models deployable, accountable, and impactful at scale.

It was a privilege to share this vision alongside the researchers, healthcare leaders, and technology builders at NVIDIA GTC Taiwan shaping the next chapter of AI.
425 replies 277 reposts 663 likes 228K views View on X
LIFE AI @LifeNetwork_AI
Mapping Diabetes Is Progress. Preventing It Is the Goal.

Half a century after geneticist James V. Neel described diabetes as โ€œa geneticistโ€™s nightmareโ€ (1976), research is mapping its genetic architecture in growing detail (Suzuki et al., Nature, 2024).

This progress matters most where the burden is heaviest. According to the IDF Diabetes Atlas (2025), around 322 million adults in the Western Pacific and South-East Asia were living with diabetes in 2024, more than half of the global total. The same report estimates that 252 million adults with diabetes worldwide remained undiagnosed in 2024. In East Asian populations, type 2 diabetes also tends to develop at a younger age and a lower body weight than in people of European descent (Ma & Chan, 2013).

Identifying genetic signals does not, by itself, prevent disease. It indicates where risk may originate. Its value depends on what follows: validation in the populations it is meant to serve, including those still underrepresented in genetic research, interpretation alongside clinical judgment, and timing early enough for prevention to make a difference. Turning knowledge into timely prevention is where much of the hardest work lies.

For nearly three years, Life AI has worked with hospital partners to study the genetic architecture of diabetes risk, with the aim of helping clinicians identify individual risk earlier and personalize prevention. It is an important step, but only one. Taking diabetes off the map of chronic disease is a long-term ambition, and no single organization can achieve it alone. It is the direction Life AI will keep working toward, alongside our institutional partners.

Advances in genomics, clinical research and AI will continue to deepen our understanding of diabetes and other chronic diseases. But knowledge alone does not change outcomes. That takes health systems, clinicians, researchers and industry working together to carry it into prevention and care.

Today is World Diabetes Day. Let it remind all of us, across healthcare, research and industry, to turn what we know into prevention, earlier and at the scale this challenge demands.
0:51
17 replies 90 reposts 334 likes 13K views View on X
LIFE AI @LifeNetwork_AI
Medical breakthroughs do not automatically translate into better healthcare for every population.
In Episode 3 of Innovate Viet Nam Dialogues, powered by Viet Nam's National Innovation Center (NIC), our Founder & CEO, Dr. Tuan Cao, looked back on Life AI's nine-year journey through three of its most important milestones, achieved together with Genetica and institutional partners. Each marks a line of work that Life AI continues to build on today.

1. Genetic research in underrepresented populations
One milestone in this work was Southeast Asia's largest autism study at the time, which identified 23 new variants and added them to the global autism gene map. Those findings now form part of the genetic reference that research centers worldwide can draw on to develop diagnosis and care better suited to children in the region.

2. Genetic insight into chronic disease
Diabetes, whose genetics researchers have called "a nightmare," is a central focus of this work. Over nearly three years, Life AI and Genetica worked with hospital partners to map the genetic architecture of diabetes risk in an underrepresented patient population, contributing insight that researchers and drug developers can use toward more personalized prevention and treatment.

3. AI inside the hospital
Connecting hospitals and putting AI to work across them remains a persistent challenge in healthcare. Life Cloud, our federated healthcare AI platform, addresses it by bringing AI capabilities directly into hospitals, so that AI creates value where care is delivered. It is now in pilot deployment, with a roadmap to expand across Southeast Asia.

Many genetic risk models are still built primarily on people of European ancestry, leaving much of the world's population underrepresented. From the lab to the hospital, each of these milestones narrows that gap a little further, and together they form the foundation for Life AI's focus today: applying AI to advance precision medicine and drug research that also serve underrepresented populations.
3:18
25 replies 86 reposts 225 likes 16K views View on X
LIFE AI @LifeNetwork_AI
Healthcare AI is getting better at identifying risk, and bringing the right partners together can turn that capability into a service.

AI can find the signal, but healthcare needs infrastructure to act on it. That is what Life AI is building with Life Cloud, a connected healthcare network, around one principle: bring intelligence to where care happens.

Care happens in hospitals. They are where clinical knowledge originates, and they hold what turns a signal into care: laboratories, specialists and clinical judgment.

But a patientโ€™s path rarely stays within one hospital, and prevention can stall between signal and care, often in the handoffs between hospitals.

Closing that gap takes two things: intelligence that works inside each hospital, and a network that connects them. In Life Cloud, each hospital joins as a node. The AI flags; the doctor makes the final clinical decision.

Thalassemia screening, one of Life Cloudโ€™s applications, shows what that involves.
It is one of the most common inherited disorders worldwide, especially in Southeast Asia, and severe forms require lifelong treatment. Carriers usually have no symptoms, so the risk often goes unnoticed until a child is diagnosed, though it can be identified years earlier.
A routine blood count, where AI can flag signs of the trait, is only the first step. Confirmatory testing, genetic counseling and partner screening must follow, often at different facilities. Partner screening is often the most fragile link.

For health systems, things may come to those who wait, but only the things left by those who hustle.

Where that sequence is connected, families can be reached in time.
In Guangxi, China, an information system tracks each high-risk couple, and screening coverage reached 99.99% in 2024. One remaining gap, a 2026 review notes, is linking systems across provinces. Life Cloud is designed to connect the institutions patients move between.

Models must also hold up across populations. Carrier rates in Vietnam range from under 10% among the Kinh majority to 40% in some ethnic groups, so a model validated in one group must be checked in others. Every hospital that joins makes that possible for more people.
The aim is not to decide for families, but to give them accurate information and counseling early enough to make their own choices.

Life Cloud is at an early stage, in closed testing with a few hospitals, and the thalassemia application is in development. It will be judged in care, by whether the pathway can be completed reliably. Longer term, a network this diverse could support research into how medicines work in Asian populations.

Life Cloud will grow one node at a time. Each hospital, research institution, pharmaceutical company and technology partner that joins extends what the network can do for patients.

We look forward to building it with those addressing similar challenges.